Thetis Pharmaceuticals LLC
Deep River, CT
- UEI
- QBDWD3M7YKM9
- CAGE
- 6UY21
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 80 Meadow Woods Rd, Deep River, CT 06417, USA
- Website
- thetispharma.com
- Founded
- 2011
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Max Biopharma, Inc. | Santa Monica, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Quercus Molecular Design, LLC | Avon, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biotherapeutics, Inc. | Blacksburg, VA | — |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Trethera Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Thetis Pharmaceuticals LLC is a for-profit limited liability company focused on developing novel therapeutics for the treatment of inflammatory diseases and cancer. Through federal grant awards, Thetis Pharmaceuticals provides research and development services to advance its pipeline of drug candidates into clinical trials.
Thetis has received four prime federal grants totaling over $3.8 million from the National Institutes of Health to support development of its resolvin-based drug candidates. These grants funded efficacy studies in animal models of disease, IND-enabling toxicology studies, and manufacturing of clinical trial materials for multiple Thetis drug candidates including TP-317 for pancreatic cancer and acute respiratory distress syndrome, and TP-352 for pediatric non-alcoholic steatohepatitis. Additional federal funding has supported development of Thetis' pipeline for other inflammatory conditions such as eosinophilic esophagitis. Key services provided through these awards include preclinical pharmacology and toxicology studies, drug manufacturing and testing, and regulatory filing support to enable clinical advancement of Thetis' therapeutic candidates.
Quick answers
Is Thetis Pharmaceuticals LLC registered in SAM.gov?
Yes. Thetis Pharmaceuticals LLC's SAM.gov registration is active through September 17, 2027.
What is Thetis Pharmaceuticals LLC's most recent federal award?
Thetis Pharmaceuticals LLC's most recent federal grant award is Development of a novel resolvin-based therapy for treatment of pancreatic cancer (R44CA278026), from National Cancer Institute (NIH), on June 2, 2023.
On GovTribe
See Thetis Pharmaceuticals LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors